Announcement • Jun 14
Perk Labs Inc. announced that it expects to receive CAD 2.5 million in funding Perk Labs Inc. announced a non-brokered private placements of units and convertible debentures on June 12, 2024. The Company is proposing a new non-brokered private placement of up to 115,384,615 units at a price of CAD 0.013 per Unit for gross proceeds of up to CAD 1,499,999.995 and convertible debentures for gross proceeds of up to CAD 1,000,000; aggregate gross proceeds of CAD 2,499,999.995. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the Closing. The convertible debentures will be offered for a 2-year term at an interest rate of 15% and will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share. The private placements of the Units and the convertible debentures are expected to close on or before June 29, 2024. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placements will be subject to a statutory hold period of four months and one day following the Closing. A finder’s fee may be payable in connection with the Private Placements. New Risk • May 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended August 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (38% average weekly change). Revenue is less than US$1m (CA$63k revenue, or US$46k). Market cap is less than US$10m (CA$7.52m market cap, or US$5.52m). Minor Risks Latest financial reports are more than 6 months old (reported August 2023 fiscal period end). Shareholders have been diluted in the past year (22% increase in shares outstanding). Announcement • Apr 26
Perk Labs Inc. announced that it has received CAD 1.714 million in funding On April 25, 2024, Perk Labs Inc. closed the transaction. The company announced that it has issued 78,900,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 789,000 and 15% convertible debentures for the gross proceeds of CAD 25,000; aggregate gross proceeds of CAD 814,000 in third and final tranche. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature two years from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share, subject to the terms and conditions set forth in the specific Debenture agreement. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. In connection with private placements, B. Rogic acquired CAD 73,000 of Units 
